miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer

Chiara Molinari,1 Samanta Salvi,1 Flavia Foca,2 Nazario Teodorani,3 Luca Saragoni,4 Maurizio Puccetti,5 Alessandro Passardi,6 Stefano Tamberi,7 Andrea Avanzolini,8 Enrico Lucci,8 Daniele Calistri1 1Biosciences Laboratory, 2Unit of Biostatistics and Clinical Trials, 3Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, 4Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, 5Pathology Unit, Santa Maria delle Croci Hospital, Ravenna, 6Department of Medical Oncology, IRST IRCCS, Meldola, 7Department of Medical Oncology, Infermi Hospital, Faenza, 8Department of General Surgery, Morgagni-Pierantoni Hospital, Forlì, Italy Abstract: Neoadjuvant chemoradiotherapy (NCRT) followed by surgery is the gold standard for the treatment of patients with locally advanced rectal cancer (LARC). However, response is variable, and no predictive markers have been validated. The amplification of 13q31–34 seemed to distinguish between nonresponders and responders to NCRT. The miR-17-92a-1 cluster host gene (MIR17HG), which is involved in the development, progression, and aggressiveness of colorectal cancer, and the ABCC4 gene, an ATP-binding cassette transporter, are located at this region. Moreover, the transcription factor c-Myc is closely related to MIR17HG. The aim of this study was to examine the role of MIR17HG, ABCC4, and CMYC gene copy numbers (CNs) in determining response to NCRT. We analyzed DNA CN of pretherapy...
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research